Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsParkland Rituximab Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentParkland Community Health PlanPolicy N/A

    Rituximab (Rituxan) Off-Label Therapy Coverage Criteria

    Customize your policy alerts

    Sign up for all parklandcommunityhealthplan policy alerts

    Know when parklandcommunityhealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization standards for off-label clinician-administered rituximab and applicable biosimilars for Parkland Community Health Plan STAR and CHIP members.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyRituximab (Rituxan) Off-Label Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for off-label clinician-administered rituximab or an applicable biosimilar, including indication-specific medical-necessity documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered off-label indication groups
    12 moMaximum MS authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 mo
    Nephrotic syndrome authorization
    6 moSLE authorization interval
    4Maximum weekly doses

    Coverage Criteria

    Multiple Sclerosis - Initial Therapy

    Covered for initial multiple sclerosis therapy when ALL criteria are met.

    Initial therapy for MS

    • Eligible MS subtype

      • Diagnosis of primary progressive multiple sclerosis.
      • Diagnosis of relapsing forms of multiple sclerosis, including relapsing-remitting MS, secondary-progressive MS with relapses, or progressive-relapsing MS with relapses.
    • No prohibited combination therapy: Patient is not receiving rituximab with disease-modifying therapy, B-cell targeted therapy, or lymphocyte trafficking blockers.

      Examples include interferon beta preparations, dimethyl fumarate, glatiramer acetate, natalizumab, fingolimod, cladribine, siponimod, teriflunomide, ocrelizumab, belimumab, ofatumumab, alemtuzumab, or mitoxantrone.

    Multiple Sclerosis - Continuation and Reauthorization

    Covered for continuation of multiple sclerosis therapy when ALL criteria are met.

    Continuation and reauthorization for MS: Patient is not receiving rituximab with disease-modifying therapy, B-cell targeted therapy, or lymphocyte trafficking blockers; neurologic function has stabilized or improved; relapse frequency has been reduced; there are no new contraindications or intolerances; and there has been no infusion-related anaphylaxis, serious infection, or prolonged hypogammaglobulinemia unless appropriately managed.Approval timeframe no more than 12 months

    Nephrotic Syndrome - Initial Therapy

    Covered for nephrotic syndrome when ALL criteria are met.

    Initial therapy for nephrotic syndrome

    • Qualifying histological subtype

      • Idiopathic membranous nephropathy (IMN).
      • Focal segmental glomerulosclerosis (FSGS).
      • Minimal change disease (MCD).
      • Membranoproliferative glomerulonephritis (MPGN).
      • Lupus nephritis.

    Nephrotic Syndrome - Continuation and Reauthorization

    Covered for nephrotic syndrome reauthorization when ALL criteria are met.

    Continuation and reauthorization for nephrotic syndrome: There is improvement or stability in organ function, such as kidney function; serum albumin is stable or improved; proteinuria is reduced or remission is maintained; there are no new contraindications or intolerances; and there has been no infusion-related anaphylaxis, serious infection, or prolonged hypogammaglobulinemia unless appropriately managed.Approval timeframe 6 months

    Systemic Lupus Erythematosus - Initial Therapy

    Covered for SLE when ALL criteria are met.

    Initial therapy for systemic lupus erythematosus

    • Severe disease manifestation

      • Class III, IV, or V lupus nephritis, established by biopsy or clinical diagnosis.
      • Refractory autoimmune cytopenia, such as thrombocytopenia or hemolytic anemia.
      • Neuropsychiatric lupus.
      • Other severe organ-threatening disease manifestation.
    • Required prior therapy failure or intolerance:

    Systemic Lupus Erythematosus - Continuation and Reauthorization

    Covered for SLE reauthorization when ALL criteria are met.

    Continuation and reauthorization for SLE: There is reduced relapse frequency; improvement or stability in organ function, proteinuria, or renal function; documented clinical improvement or stabilization, such as reduced proteinuria, improved platelet counts, or decreased corticosteroid use; no new contraindications or intolerances; and no infusion-related anaphylaxis, serious infection, or prolonged hypogammaglobulinemia unless appropriately managed.Approval timeframe 6 months; repeat cycles no more frequently than every 6 months unless strongly justified

    Coverage requires that rituximab not be administered concurrently with prohibited therapies for the applicable indication. For multiple sclerosis, prohibited combinations include disease-modifying therapies, B-cell-targeted therapies, and lymphocyte-trafficking blockers. For nephrotic syndrome, rituximab must not be used with another biologic DMARD or a Janus kinase (JAK) inhibitor.

    Coding and Dosing

    Rituximab and biosimilar HCPCS codesHCPCSCovered
    J9312Injection Rituximab, 10mg
    Q5115Injection Rituximab-abbs, biosimilar 10mg
    Q5119Injection Rituximab-pvvr, biosimilar 10mg
    Q5123Injection Rituximab-arrx, biosimilar 10mg
    Multiple SclerosisICD-10Covered
    G35Multiple Sclerosis (MS)
    Nephrotic SyndromeICD-10Covered
    N04.9Nephrotic Syndrome
    N05.8Nephrotic Syndrome
    Systemic Lupus ErythematosusICD-10Covered
    M.32.9Systemic Lupus Erythematosus
    Nephrotic Syndrome Standard Dose
    Dose375 mg/m2 per IV infusion
    FrequencyOnce weekly
    Course limitUp to 4 doses
    SLE Standard Dose
    Dose375 mg/m2 per dose
    FrequencyWeekly
    Course limit

    Provider Requirements and Decision Risks

    Prior Authorization

    Prior Authorization Required for Off-Label CAD Use

    Prior authorization is required for off-label rituximab or an applicable biosimilar administered as a clinician-administered drug to STAR or CHIP members. Submit the indication, clinical rationale, supporting documentation, and requested regimen for MS, nephrotic syndrome, or SLE.

    • Applies to off-label use not explicitly approved by the FDA.
    • Initial authorization is limited to the timeframe specified for the indication: MS up to 12 months; nephrotic syndrome 6 months; SLE 6 months.
    Step Therapy

    MS Requires Second-Line Therapy

    Rituximab may be considered a second-line option for refractory or relapsing multiple sclerosis after failure of first-line therapy.

    • Eligible MS subtypes include primary progressive MS and relapsing forms, including relapsing-remitting MS and secondary-progressive MS with relapses.
    • Document the first-line therapy previously used, treatment failure or inadequate response, and the clinical rationale for second-line treatment.

    Clinical Background

    Rituximab is considered under this policy for selected off-label autoimmune and inflammatory conditions when disease severity, prior treatment response, and safety monitoring support medical necessity. Covered clinical contexts include multiple sclerosis, nephrotic syndrome associated with specified histologic subtypes, and severe systemic lupus erythematosus. Coverage is limited to cases meeting the condition-specific treatment history, dosing, monitoring, and safety requirements.

    Definitions

    Unapproved Indication / Off-Label Use
    DefinitionA health care provider prescribes a medication for an unapproved use when deemed medically appropriate for the member.
    Different disease or conditionUse for a disease or medical condition that the medication is not approved to treat.
    Different route or formulationAdministration in a different way than the approved formulation, such as using an oral solution instead of a capsule.
    Different doseUse at a dose different from the approved dose.
    Biosimilars
    Separate identificationGeneric or biosimilar products are identified separately from the brand-name product for the listed HCPCS codes.

    Initial Therapy

    Multiple Sclerosis Initial Therapy

    Covered for initial multiple sclerosis therapy when ALL criteria are met.

    MS initial therapy

    • Eligible MS subtype

      • Primary progressive multiple sclerosis.
      • Relapsing forms of MS, including relapsing-remitting MS, secondary-progressive MS with relapses, or progressive-relapsing MS with relapses.
    • No prohibited combination therapy: Patient is not receiving rituximab with disease-modifying therapy, B-cell targeted therapy, or lymphocyte trafficking blockers.

    Nephrotic Syndrome Initial Therapy

    Continuation and Reauthorization

    Multiple Sclerosis Continuation

    Multiple sclerosis continuation therapy requires ALL criteria below.

    MS continuation: No prohibited combination therapy; neurologic function has stabilized or improved; relapse frequency has been reduced; there are no new contraindications or intolerances; and there has been no infusion-related anaphylaxis, serious infection, or prolonged hypogammaglobulinemia unless appropriately managed.Authorization no more than 12 months

    Nephrotic Syndrome Continuation

    Nephrotic syndrome continuation requires ALL criteria below.

    Nephrotic syndrome continuation: There is improvement or stability in organ function, stable or improved serum albumin, reduced proteinuria or maintained remission, no new contraindications or intolerances, and no infusion-related anaphylaxis, serious infection, or prolonged hypogammaglobulinemia unless appropriately managed.Approval timeframe 6 months

    Step Therapy Requirements

    StepPrerequisite therapyCoverage
    1Failure of first-line therapyRituximab may be considered as a second-line option for refractory or remitting multiple sclerosis after first-line therapy failure.
    StepPrerequisite therapyCoverage
    1Failure of oral corticosteroids, unless contraindicated or clinically significant adverse effects are documented; and failure of one listed immunosuppressant—cyclophosphamide, chlorambucil, tacrolimus, cyclosporine, or mycophenolate mofetil—unless contraindicated or clinically significant adverse effects are documented.Rituximab may be considered after the required treatment failures or documented exceptions.
    StepPrerequisite therapyCoverage
    1Failure, intolerance, or contraindication to at least two conventional immunosuppressive agents: mycophenolate mofetil, azathioprine, cyclophosphamide, methotrexate, belimumab, or high-dose corticosteroids (≥20 mg/day prednisone or equivalent).Rituximab may be considered after the required prior treatment history is documented.

    Quantity and Authorization Limits

    Rituximab Quantity Limit — Nephrotic Syndrome
    DrugRituximab
    Dose per infusion375 mg/m2 IV
    FrequencyOnce weekly
    Maximum course quantityUp to 4 doses per course
    Rituximab Quantity Limit — SLE
    DrugRituximab
    Dose per dose375 mg/m2

    Rituximab Biosimilars

    Billing Rule

    Use the applicable Truxima biosimilar code

    Bill rituximab (Rituxan) under HCPCS J9312, described as Injection Rituximab, 10 mg. The applicable biosimilar code for rituximab-abbs (Truxima) is Q5115.

    • Q5115: Injection Rituximab-abbs, biosimilar 10 mg (Truxima).
    Billing Rule

    Use the applicable Ruxience biosimilar code

    Bill rituximab (Rituxan) under HCPCS J9312, described as Injection Rituximab, 10 mg. The applicable biosimilar code for rituximab-pvvr (Ruxience) is Q5119.

    • Q5119: Injection Rituximab-pvvr, biosimilar 10 mg (Ruxience).
    Policy Summary
    PayerParkland Community Health Plan
    PolicyRituximab (Rituxan) Off-Label Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for off-label clinician-administered rituximab or an applicable biosimilar, including indication-specific medical-necessity documentation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and DosingProvider Requirements and Decision RisksClinical BackgroundDefinitionsInitial TherapyContinuation and ReauthorizationStep Therapy RequirementsQuantity and Authorization LimitsRituximab Biosimilars
    IgA nephropathy.
  1. Specialist involvement: Rituximab is prescribed by or in consultation with a nephrologist.
  2. Required prior therapy: Oral corticosteroids have failed, unless contraindicated or clinically significant adverse effects are documented, and one of cyclophosphamide, chlorambucil, tacrolimus, cyclosporine, or mycophenolate mofetil has failed, unless contraindication or clinically significant adverse effects are documented.
  3. Acceptable dosing basis: Dose does not exceed 375 mg/m2 IV infusion once weekly up to 4 doses, or the dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use with supporting evidence submitted.375 mg/m2 IV infusion once weekly up to 4 doses
  4. Failure, intolerance, or contraindication to at least two of mycophenolate mofetil, azathioprine, cyclophosphamide, methotrexate, belimumab, or high-dose corticosteroids.
    At least 2 agents; high-dose corticosteroids defined as ≥20 mg/day prednisone or equivalent
  5. Treatment, monitoring, and safety plan: Treatment plan uses 375 mg/m2 weekly for 4 doses and includes baseline and periodic CBC, renal function, urinalysis, and B-cell count if available; HBV, HCV, HIV, and tuberculosis screening before initiation; premedication to prevent infusion reactions; and a plan to assess treatment response.
  6. 4 doses
    SLE Minimum Age
    Minimum age≥ 6 years
    DiagnosisConfirmed SLE classification criteria
    Disease requirementAt least one severe organ-threatening manifestation
    SLE Retreatment Interval
    Minimum retreatment intervalNo more frequently than every 6 months
    ExceptionMore frequent retreatment may be used when clinical evidence supports it; repeat cycles require strong justification
    Approval timeframe6 months
    Step Therapy

    Nephrotic Syndrome Treatment Failures Required

    For nephrotic syndrome, document failure of oral corticosteroids unless contraindication or clinically significant adverse effects are documented, plus failure of at least one specified immunosuppressant unless clinically significant adverse effects or a contraindication are documented.

    • Required corticosteroid history: failed oral corticosteroid therapy, or documented contraindication or clinically significant adverse effects.
    • Required additional treatment history: failure of one of cyclophosphamide, chlorambucil, tacrolimus, cyclosporine, or mycophenolate mofetil, unless clinically significant adverse effects or contraindication apply.

    Unsupported block type: step_therapy

    Documentation Required

    Nephrotic Syndrome Documentation

    Requests for nephrotic syndrome must include the qualifying diagnosis and histological subtype, nephrologist involvement, required treatment failures, and supporting clinical documentation.

    • Qualifying subtypes: idiopathic membranous nephropathy, focal segmental glomerulosclerosis, minimal change disease, membranoproliferative glomerulonephritis, lupus nephritis, or IgA nephropathy.
    • Rituximab must be prescribed by or in consultation with a nephrologist.
    • Include clinical records supporting diagnosis, subtype, corticosteroid and immunosuppressant history, contraindications or adverse effects, and the requested regimen.
    Documentation Required

    SLE Documentation Requirements

    SLE requests must document the patient’s age, confirmed classification diagnosis, disease severity and organ involvement, prior treatment history, and the proposed treatment and monitoring plan.

    • Patient must be at least 6 years old and meet confirmed SLE classification criteria.
    • Document at least one severe manifestation, such as class III, IV, or V lupus nephritis; refractory autoimmune cytopenia; neuropsychiatric lupus; or another severe organ-threatening manifestation.
    • Include the treatment history supporting failure, intolerance, or contraindication to at least two qualifying agents.
    Documentation Required

    MS Clinical Documentation

    MS requests must identify the disease subtype, demonstrate failure of first-line therapy, reconcile current medications, and confirm that rituximab will not be used with prohibited therapies.

    • Identify PPMS or a qualifying relapsing form of MS.
    • Submit first-line treatment history and the reason it failed or was inadequate.
    • Document current disease-modifying therapies, B-cell targeted therapies, and lymphocyte trafficking blockers before initiation and at reauthorization.
    Documentation Required

    Support Off-Label Dosing Variations

    When the requested nephrotic syndrome regimen differs from the stated regimen, the provider must submit practice-guideline or peer-reviewed literature supporting the proposed off-label dose.

    • Standard dosing option: no more than 375 mg/m² by IV infusion once weekly for up to 4 doses.
    • For dosing outside this regimen, provide relevant guideline or peer-reviewed literature and explain its applicability to the patient’s indication.
    Denial Risk

    MS Prohibited Combination Therapy

    Rituximab is not medically necessary for MS when administered concurrently with specified disease-modifying, B-cell targeted, or lymphocyte trafficking therapies.

    • Prohibited disease-modifying therapies include interferon beta preparations, dimethyl fumarate, glatiramer acetate, natalizumab, fingolimod, cladribine, siponimod, and teriflunomide.
    • Prohibited B-cell targeted therapies include ocrelizumab, belimumab, and ofatumumab.
    • Prohibited lymphocyte trafficking blockers include alemtuzumab and mitoxantrone.
    Denial Risk

    Nephrotic Syndrome Prerequisites and Safety

    A nephrotic syndrome request may be denied when required prerequisite treatment failures are not established or when rituximab is requested with unsafe concurrent therapy.

    • Denial risk applies when oral corticosteroid failure is absent and no qualifying contraindication or clinically significant adverse effect is documented.
    • Denial risk applies when failure of at least one specified immunosuppressant is absent and no qualifying exception is documented.
    • Do not use concurrently with other biologic disease-modifying antirheumatic drugs or Janus kinase inhibitors.
    Denial Risk

    SLE Eligibility and Denial Risks

    SLE requests may be denied when age, diagnosis, severity, organ involvement, or required prior treatment history is insufficiently documented.

    • Patient must be at least 6 years old.
    • A confirmed SLE classification diagnosis is required.
    • Document severe organ-threatening disease or another qualifying severe manifestation.
    • Document failure, intolerance, or contraindication to at least two listed conventional immunosuppressive agents.
    Denial Risk

    Reauthorization Response and Safety Requirements

    Reauthorization requires evidence of clinical benefit and no unmanaged safety concern. Requests may be denied for inadequate response, new contraindications or intolerances, serious infusion or infectious complications, or treatment intervals that exceed policy limits.

    • MS: document stabilization or improvement in neurologic function and reduced relapse frequency; no new contraindications or intolerances.
    • Nephrotic syndrome: document improved or stable kidney or other organ function, stable or improved serum albumin, reduced proteinuria or maintained remission, and no new contraindications or intolerances.
    • SLE: document reduced relapse frequency, improved or stable organ function and proteinuria or renal function, clinical improvement or stabilization, and no new contraindications or intolerances.
    • For all indications, address infusion-related anaphylaxis, serious infections, or prolonged hypogammaglobulinemia; repeat SLE cycles no more frequently than every 6 months unless strongly justified.
    Reference productRituximab (Rituxan)
    Biosimilar productsRituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni)
    HCPCS codesQ5115, Q5119, and Q5123 identify the listed biosimilars; J9312 identifies rituximab.

    Nephrotic syndrome initial therapy requires ALL policy criteria.

    Nephrotic syndrome initial therapy

    • Qualifying histological subtype

      • Idiopathic membranous nephropathy, focal segmental glomerulosclerosis, minimal change disease, membranoproliferative glomerulonephritis, lupus nephritis, or IgA nephropathy.
    • Acceptable dosing basis: Dose does not exceed 375 mg/m2 IV infusion once weekly up to 4 doses, or supporting evidence is submitted for the relevant off-label dose.375 mg/m2 IV infusion once weekly up to 4 doses

    Systemic Lupus Erythematosus Initial Therapy

    SLE initial therapy requires ALL policy criteria.

    SLE initial therapy

    • Severe disease manifestation

      • Class III, IV, or V lupus nephritis; refractory autoimmune cytopenia; neuropsychiatric lupus; or another severe organ-threatening disease manifestation.
    • Required prior therapy: Failure, intolerance, or contraindication to at least two of mycophenolate mofetil, azathioprine, cyclophosphamide, methotrexate, belimumab, or high-dose corticosteroids.At least 2 agents; high-dose corticosteroids defined as ≥20 mg/day prednisone or equivalent
    • Monitoring and safety plan: Plan includes baseline and periodic CBC, renal function, urinalysis, and B-cell count if available; HBV, HCV, HIV, and tuberculosis screening before initiation; premedication to prevent infusion reactions; and a plan for assessing treatment response.

    Systemic Lupus Erythematosus Continuation

    SLE continuation requires ALL criteria below.

    SLE continuation: Relapse frequency has been reduced; organ function, proteinuria, or renal function has improved or remained stable; clinical improvement or stabilization is documented; there are no new contraindications or intolerances; and there has been no infusion-related anaphylaxis, serious infection, or prolonged hypogammaglobulinemia unless appropriately managed.Repeat cycles no more frequently than every 6 months unless strongly justified; approval timeframe 6 months
    Frequency
    Weekly
    Maximum course quantity4 doses per course
    Billing Rule

    Use the applicable Riabni biosimilar code

    Bill rituximab (Rituxan) under HCPCS J9312, described as Injection Rituximab, 10 mg. The applicable biosimilar code for rituximab-arrx (Riabni) is Q5123.

    • Q5123: Injection Rituximab-arrx, biosimilar 10 mg (Riabni).